Filtered By:
Infectious Disease: Hepatitis B
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 38 results found since Jan 2013.
Efficacy of Entecavir Switching Therapy in Chronic Hepatitis B Patients with Clevudine-induced Myopathy.
Conclusions: In chronic hepatitis B patients experiencing clevudine-induced myopathy, switching to entecavir 0.5 mg per day showed a resolution of myopathy and adequate viral suppression. (Korean J Gastroenterol 2013;61:30-36).
PMID: 23354347 [PubMed - in process]
Source: Korean J Gastroenter... - January 25, 2013 Category: Gastroenterology Authors: Lee JW, Lee YJ, Lee JJ, Kim JH, Jung YK, Kwon OS, Choi DJ, Kim YS, Kim JH Tags: Korean J Gastroenterol Source Type: research
Clevudine Induced Mitochondrial Myopathy.
Authors: Park SH, Park KS, Kim NH, Cho JY, Koh MS, Lee JH
Abstract
Clevudine was approved as an antiviral agent for hepatitis B virus, which showed marked, rapid inhibition of virus replication without significant toxicity. However, several studies have reported myopathy associated with clevudine therapy. Also, we experienced seven patients who suffered from myopathy during clevudine therapy. To characterize clevudine-induced myopathy, we collected previously reported cases of clevudine myopathy and analyzed all the cases including our cases. We searched electronic databases that were published in English or Korean...
Source: Journal of Korean Medical Science - September 30, 2017 Category: Biomedical Science Tags: J Korean Med Sci Source Type: research
Telbivudine in liver transplant recipients: Renal protection does not overcome the risk of polyneuropathy and myopathy
In conclusion, although it seems to have a favorable effect in the improvement of renal function and to be effective in the prevention of HBV recurrence, the high risk of polyneuropathy and myopathy hamper the use of telbivudine in LT recipients. This article is protected by copyright. All rights reserved.
Source: Liver Transplantation - April 2, 2015 Category: Transplant Surgery Authors: Ilker Turan, Suna Yapali, Fikret Bademkiran, Timur Kose, Soner Duman, Murat Sozbilen, Fulya Gunsar, Galip Ersoz, Ulus Salih Akarca, Omer Ozutemiz, Zeki Karasu Tags: Original Articles Source Type: research
Telbivudine-Induced Myopathy: Clinical Features, Histopathological Characteristics, and Risk Factors
CONCLUSIONS: Mitochondrial abnormalities are characteristic histopathological features, and impaired renal function and HBeAg positivity are risk factors for TIM. Telbivudine-induced mitochondrial dysfunction and immune activation related to mitochondrial damage and HBeAg serostatus changes may underlie TIM. Constant clinical surveillance of myopathy during telbivudine treatment is needed due to the significant latency of its development. Dose adjustment for impaired renal function does not eliminate the risk of TIM occurrence.PMID:36606646 | DOI:10.3988/jcn.2023.19.1.52
Source: Journal of Clinical Neurology - January 6, 2023 Category: Neurology Authors: Min-Yu Lan Hui-Chen Lin Tsung-Hui Hu Shu-Fang Chen Chien-Hung Chen Yung-Yee Chang King-Wah Chiu Tsu-Kung Lin Shun-Sheng Chen Source Type: research
Insights into the mechanisms of telbivudine-induced myopathy associated with mitochondrial dysfunction
In conclusion, our study provides compelling evidence suggesting that telbivudine-induced myopathy is associated with mitochondrial toxicity and impaired energy metabolism. The observed muscle pathology, depletion of mtDNA, elevation of oxidative stress and altered mitochondrial function support the hypothesis that telbivudine disrupts mitochondrial homeostasis, ultimately leading to muscle damage. This may be also a common mechanism for NAs to cause neuromyopathy.PMID:37659625 | DOI:10.1016/j.cbi.2023.110692
Source: Chemico-Biological Interactions - September 2, 2023 Category: Molecular Biology Authors: Wenfei Yu Zhuxvn Li Wenjing Wu Dandan Zhao Chuanzhu Yan Pengfei Lin Source Type: research
Entecavir‐associated myopathy: a case report and literature review
Conclusion: Patients who receive NA therapy should be closely monitored for myopathic side effects. © 2013 Wiley Periodicals, Inc.
Source: Muscle and Nerve - November 12, 2013 Category: Internal Medicine Authors: Kai Yuan, Guochun Wang, Zhenguo Huang, Bing Lin, Huiqiong Zhou, Xin Lu Tags: Research Article Source Type: research
